Interaction Checker

Octreotide interactions

Octreotide (Sandostatin, Bynfezia, Mycapssa) has 125 documented interactions across the FDA labels and fact sheets we index: 0 major, 125 moderate, 0 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Moderate interactions (125)

  • AcarboseantidiabeticModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Acebutololbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • AlogliptinDPP-4 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Alogliptin and metforminDPP-4 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Amlodipinedihydropyridine calcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Amlodipine and atorvastatindihydropyridine calcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Amlodipine and benazeprildihydropyridine calcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Amlodipine and olmesartandihydropyridine calcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Amlodipine and valsartandihydropyridine calcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Antacids (Tums, Maalox, Mylanta)OTC productModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • Atenololbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Atenolol and chlorthalidonebeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Betaxololbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • BexagliflozinSGLT2 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Bisoprololbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Bisoprolol and hydrochlorothiazidebeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Brimonidine and timololalpha-adrenergic agonistModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Bromocriptinedopamine agonistModerate

    Bromocriptine: dose adjustment of bromocriptine may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • CanagliflozinSGLT2 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Carvedilolbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • CimetidineH2 blockerModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • Conjugated estrogensestrogenModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • Conjugated estrogens and bazedoxifeneestrogenModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • CyclosporineimmunosuppressantModerate

    Cyclosporine : may have decreased bioavailability and require dose adjustment ( 7 ). (Octreotide label, Drug interactions)

  • DapagliflozinSGLT2 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Dapagliflozin and metforminSGLT2 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Desogestrel and ethinyl estradioloral contraceptiveModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • Dexlansoprazoleproton pump inhibitorModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • Dextromethorphan and quinidineserotonergic drugModerate

    Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required (‎ 7 ). (Octreotide label, Drug interactions)

  • Digoxindigitalis glycosideModerate

    Digoxin: exposure may be decreased and assessment of clinical response to digoxin should be performed (‎ 7 ). (Octreotide label, Drug interactions)

  • Diltiazemcalcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Dorzolamide and timololcarbonic anhydrase inhibitorModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Drospirenone and ethinyl estradioloral contraceptiveModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • DulaglutideGLP-1 receptor agonistModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • EmpagliflozinSGLT2 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Empagliflozin and metforminSGLT2 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Esmololbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Esomeprazoleproton pump inhibitorModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • Esterified estrogens and methyltestosteroneestrogenModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • EstradiolestrogenModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • Estradiol and dienogestoral contraceptiveModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • Estradiol and norethindroneestrogenModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • Ethynodiol diacetate and ethinyl estradioloral contraceptiveModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • Etonogestrel and ethinyl estradiolestrogenModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • ExenatideGLP-1 receptor agonistModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • FamotidineH2 blockerModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • Felodipinedihydropyridine calcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • FulvestrantestrogenModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • GlimepiridesulfonylureaModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • GlipizidesulfonylureaModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Glipizide and metforminsulfonylureaModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • GlucagonModerate

    Hyperglycemia and Hypoglycemia MYCAPSSA alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone, which may result in hypoglycemia, or hyperglycemia, or diabetes mellitus. (Octreotide label, Warnings and precautions)

  • GlyburidesulfonylureaModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Glyburide and metforminsulfonylureaModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Ibuprofen and famotidineNSAIDModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • Insulin aspartinsulinModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Insulin degludecinsulinModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Insulin detemirinsulinModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Insulin glargineinsulinModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Insulin lisproinsulinModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Insulin regular (human)insulinModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Isradipinedihydropyridine calcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Labetalolbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Lansoprazoleproton pump inhibitorModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • LevonorgestrelprogestinModerate

    Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (‎12.3) ] . (Octreotide label, Drug interactions)

  • Levonorgestrel and ethinyl estradioloral contraceptiveModerate

    Levonorgestrel Clinical Impact: Concomitant administration of MYCAPSSA with levonorgestrel decreases levonorgestrel bioavailability [see Clinical Pharmacology (‎12.3) ] . (Octreotide label, Drug interactions)

  • Levothyroxinethyroid hormoneModerate

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Octreotide label, Warnings and precautions)

  • Levothyroxine and liothyroninethyroid hormoneModerate

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Octreotide label, Warnings and precautions)

  • LinagliptinDPP-4 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Linagliptin and metforminDPP-4 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Liothyroninethyroid hormoneModerate

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Octreotide label, Warnings and precautions)

  • LiraglutideGLP-1 receptor agonistModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • LisinoprilACE inhibitorModerate

    Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). (Octreotide label, Drug interactions)

  • Lisinopril and hydrochlorothiazideACE inhibitorModerate

    Lisinopril: bioavailability may be increased, monitor patient's blood pressure and adjust dose of lisinopril if needed (‎ 7 ). (Octreotide label, Drug interactions)

  • MedroxyprogesteroneprogestinModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • MegestrolprogestinModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • MetforminbiguanideModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Methimazoleantithyroid drugModerate

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Octreotide label, Warnings and precautions)

  • Metoprololbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Metoprolol and hydrochlorothiazidebeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • MifepristoneCYP3A4 inhibitorModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • MiglitolantidiabeticModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Nadololbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Naproxen and esomeprazoleNSAIDModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • NateglinidemeglitinideModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Nebivololbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Nicardipinedihydropyridine calcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Nifedipinedihydropyridine calcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Nimodipinedihydropyridine calcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Nisoldipinedihydropyridine calcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • NizatidineH2 blockerModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • Norelgestromin and ethinyl estradiolestrogenModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • NorethindroneprogestinModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • Norethindrone and ethinyl estradioloral contraceptiveModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • Norgestimate and ethinyl estradioloral contraceptiveModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • Norgestrel and ethinyl estradioloral contraceptiveModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • Olmesartan, amlodipine, and hydrochlorothiazideangiotensin II receptor blocker (ARB)Moderate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Omeprazoleproton pump inhibitorModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • Omeprazole and sodium bicarbonateproton pump inhibitorModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • Pantoprazoleproton pump inhibitorModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • Pindololbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • PioglitazonethiazolidinedioneModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Pioglitazone and glimepiridethiazolidinedioneModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Pioglitazone and metforminthiazolidinedioneModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • ProgesteroneprogestinModerate

    Intervention: Decreased bioavailability may potentially diminish the effectiveness of combined oral contraceptives (COCs) or increase breakthrough bleeding. (Octreotide label, Drug interactions)

  • Propranololbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Propylthiouracilantithyroid drugModerate

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Octreotide label, Warnings and precautions)

  • QuinidineantiarrhythmicModerate

    Drugs Metabolized by CYP 450 Enzymes: concomitant use with other drugs mainly metabolized by CYP3A4 that have a narrow therapeutic index (e.g., quinidine) should be used with caution and increased monitoring may be required (‎ 7 ). (Octreotide label, Drug interactions)

  • Rabeprazoleproton pump inhibitorModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • RanitidineH2 blockerModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • RepaglinidemeglitinideModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • SaxagliptinDPP-4 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Saxagliptin and metforminDPP-4 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • SemaglutideGLP-1 receptor agonistModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • SitagliptinDPP-4 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Sitagliptin and metforminDPP-4 inhibitorModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Sodium bicarbonateantacidModerate

    Proton Pump Inhibitors, H2-receptor Antagonists, or Antacids: may decrease bioavailability of MYCAPSSA and the MYCAPSSA dose may need to be increased (‎ 7 ). (Octreotide label, Drug interactions)

  • Sotalolbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • Telmisartan and amlodipineangiotensin II receptor blocker (ARB)Moderate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • TelotristatModerate

    Short-Acting Octreotide Concurrent administration of short-acting octreotide with Xermelo significantly decreased the systemic exposure of telotristat ethyl and telotristat, the active metabolite. (Telotristat label, Drug interactions)

  • Teriparatidethyroid hormoneModerate

    Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Octreotide label, Warnings and precautions)

  • Timololbeta blockerModerate

    Dosage adjustments of concomitantly used drugs that have bradycardia effects (i.e. beta-blockers) may be necessary [see Drug Interactions (‎7.2) ]. (Octreotide label, Warnings and precautions)

  • TirzepatideGLP-1 receptor agonistModerate

    Hypoglycemia or Hyperglycemia: Monitor glucose and adjust antidiabetic treatment as needed (‎ 5.2 ). (Octreotide label, Warnings and precautions)

  • Verapamilcalcium channel blockerModerate

    Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (Octreotide label, Drug interactions)

  • Vitamin B12Vitamin and mineralModerate

    Change in vitamin B12 levels: Monitor vitamin B 12 levels during treatment ( 5.6 ). (Octreotide label, Warnings and precautions)

Check Octreotide against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.